top of page

NCI-2023-10539

A Phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC


This study is exploring a new way to treat early-stage non small cell lung cancer that can be removed with surgery. They're testing two drugs together: Dupilumab, which fights inflammation and Cemiplimab, which helps the immune system fight cancer. The goal is to find out if this combination treatment is safe and effective.

non-small cell lung cancers: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2024-07005

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial...

NCI-2024-02382

A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) This is a platform...

NCT-06362252

Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, andpreliminary efficacy of pan-RAF/MEK glue...

Comments


bottom of page